Eltromag 25mg (Generic Promacta) Adelaide — Eltrombopag ITP South Australia 2026

FAQ 1: What is the natural history of ITP in Adelaide's adult population and when is Eltromag 25mg initiated?

ITP in adults follows a more chronic course than in children — approximately 70-80% of adult ITP becomes chronic (persisting more than 12 months), unlike childhood ITP where 80%+ resolve spontaneously. Adelaide's Royal Adelaide Hospital haematologists classify adult ITP by duration and treatment response to guide the place of Eltrombopag. Newly diagnosed ITP (0-3 months): first-line is corticosteroids (prednisolone) with or without IVIG for acute bleeding; the goal is platelet count above 30-50 × 10⁹/L to prevent significant bleeding, not necessarily normalisation. Persistent ITP (3-12 months): second-line options introduced if steroids have failed or are causing unacceptable side effects — options include Rituximab, TPO-RAs (Eltromag, romiplostim), or splenectomy. Chronic ITP (above 12 months): sustained TPO-RA therapy with Eltromag 25mg (escalating as needed to 50-75mg) is the most commonly chosen second-line option in Adelaide's haematology practice — preferred over splenectomy in most patients given that surgery avoids splenectomy's lifelong post-splenectomy infection risk, and over Rituximab given Rituximab's time-limited and immunosuppressive response profile. Eltromag 25mg is the starting dose for Adelaide adults, with dose escalation guided by platelet response at 2-week intervals.

FAQ 2: How does the South Australian PBS listing for Eltromag compare to private supply through Unnati Pharmax?

Eltrombopag (brand Revolade) is PBS-listed in Australia for chronic ITP — PBS coverage requires confirmation of ITP diagnosis meeting specific criteria including platelet count threshold, prior treatment failure, and haematologist specialist prescription. For Adelaide ITP patients meeting PBS criteria, the standard PBS co-payment (approximately AUD $30 general, free concession) applies. Gaps in PBS Eltromag access that Unnati Pharmax addresses: patients in the initial assessment period before PBS authority is granted (authority prescriptions require PBS pre-authorisation that takes days to weeks); patients who for various reasons don't meet the current PBS indications despite clinical benefit (ITP variants, borderline criteria patients); international residents in Adelaide without Medicare; and patients who need supply continuity during PBS renewal administrative periods or while changing haematology providers. Brand Revolade at full private price in Adelaide pharmacies (when PBS is unavailable) costs AUD $300-500+ per tube — versus Eltromag 25mg from Unnati Pharmax at dramatically lower cost with WHO-GMP certification. The economic difference between PBS-covered and privately-funded Eltrombopag is substantial, making Unnati Pharmax's role as a bridge supply source clinically and financially meaningful for Adelaide's ITP community.

FAQ 3: How does South Australia's hot, dry climate affect Eltromag 25mg storage and patient wellbeing for ITP?

Adelaide's Mediterranean climate — with hot, dry summers (40°C+ heatwaves from December-February) and mild winters — creates specific Eltromag storage and ITP management considerations. Storage: Eltromag 25mg tablets require controlled room temperature (below 30°C) and protection from moisture; Adelaide's dry heat is generally less damaging to tablets than humid tropical climates, but summer heatwave temperatures in unair-conditioned spaces or vehicles can exceed 50°C, potentially affecting tablet stability — always store in air-conditioned indoor locations during Adelaide's summer months. For ITP patients specifically: Adelaide's extreme heat creates dehydration risk that can temporarily affect platelet function (dehydration concentrates blood, potentially affecting platelet adhesion tests); outdoor activity including Adelaide Hills hiking, wine region cycling, and beach activities increase bleeding injury risk that must be considered in the context of low platelet counts — Adelaide haematologists counsel ITP patients on activity modification based on their current platelet count; and summer heatstroke risk with low platelet counts carries theoretical risk of intracranial bleed from heat-related vascular stress — awareness of early heat illness symptoms and prompt cooling is particularly important for Adelaide's ITP community during heatwaves.

FAQ 4: What bleeding precautions should Adelaide ITP patients on Eltromag 25mg take for everyday activities?

ITP management requires practical bleeding precautions calibrated to the current platelet count — not blanket restriction from all activities. Adelaide haematologists use the following general platelet-count-based activity guidance: below 10 × 10⁹/L — severe restriction, hospitalisation consideration, avoid all trauma risk; 10-30 × 10⁹/L — avoid contact sports, heavy machinery, driving until count stabilises; 30-50 × 10⁹/L (Eltromag's target range) — most daily activities safe including gentle exercise, swimming, cycling with helmet; avoid collision sports, vigorous contact activities, and activities with high fall risk without protective equipment; 50-80 × 10⁹/L — most activities including moderate exercise, with caution for very high-impact sports; above 80 × 10⁹/L — nearly unrestricted, including most sports. Practical Adelaide advice: wear helmets for cycling regardless of platelet count — Barossa cycling routes and Hills trails have significant fall risk; avoid aspirin and NSAIDs (which impair platelet function) for pain management — use paracetamol instead; carry an ITP medical alert card (available through Platelet Disorder Support Association Australia) that informs emergency staff of the diagnosis; and contact the Royal Adelaide Hospital haematology team immediately for any head injury, severe bleeding, or sudden new bruising regardless of scheduled appointment time.

FAQ 5: What is the evidence for splenectomy versus prolonged Eltromag 25mg for chronic refractory ITP in Adelaide?

The decision between long-term TPO-RA therapy (Eltromag) and splenectomy for chronic refractory ITP is one of haematology's most individualised and debated treatment choices. Arguments for splenectomy in Adelaide's appropriate patients: highest durable remission rate (65-75% achieve complete response sustained for years); removes both the site of platelet destruction (anti-platelet antibody-coated platelets are destroyed by splenic macrophages) and a major site of anti-platelet antibody production; and one-time procedure rather than indefinite daily medication. Arguments for continuing Eltromag 25mg in preference to splenectomy: avoids surgical risk (laparoscopic splenectomy is safe but not risk-free — surgical mortality approximately 0.1-1%, significant morbidity in elderly or obese patients); avoids lifelong post-splenectomy infection (OPSI) risk requiring pneumococcal, meningococcal, and Haemophilus vaccination plus emergency antibiotic protocols; response prediction is imperfect — 25-35% of splenectomy patients relapse; and quality-of-life data from Adelaide's Royal Adelaide haematology follow-up shows equivalent QoL between well-controlled Eltromag patients and splenectomy responders, questioning splenectomy's QoL advantage. Current Adelaide practice: splenectomy is generally deferred unless TPO-RA therapy fails to maintain adequate platelet control or causes unacceptable side effects — reflecting the global trend toward medical management priority over surgery.